🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

5 recruiting trials

for Monoclonal Gammopathy of Renal Significance

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD NCT06418477Phase 23 sites📍 Beijing📍 Beijing📍 Guangzhou Peking University People's Hospital · Tests: Dara-CyBorD A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) NCT06083922Phase 211 sites📍 Boston📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: Cyclophosphamide, Bortezomib, Dexamethasone, Daratumumab A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH NCT05283993n/a1 site📍 Beijing Peking University First Hospital · Tests: No intervention The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in Finland NCT06889948Phase 21 site📍 Helsinki Helsinki University Central Hospital · Tests: Daratumumab National Registry of Rare Kidney Diseases NCT06065852n/a1 site📍 Bristol UK Kidney Association
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy